Zentalis Pharmaceuticals, Inc. announced that the company has initiated patient dosing in three new combination and monotherapy clinical trials.
[Zentalis Pharmaceuticals, Inc.]
6807162 nan items 1 apa default asc 1
Scientists report the efficacy of anti-programmed death 1 antibody with the P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) regimen in advanced natural killer/T cell lymphoma.
[Signal Transduction and Targeted Therapy]
6445218 NIW37BLL items 1 apa default asc 1
Cai, J., Liu, P., Huang, H., Li, Y., Ma, S., Zhou, H., Tian, X., Zhang, Y., Gao, Y., Xia, Y., Zhang, X., Yang, H., Li, L., & Cai, Q. (2020). Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduction and Targeted Therapy, 5(1), 1–9. https://doi.org/10.1038/s41392-020-00331-3 Cite
Investigators showed that positive coactivator 4 (PC4) orchestrated chromatin structure and gene expression in mature B cells. B-cell-specific PC4-deficient mice showed impaired production of antibody upon antigen stimulation.
6445218 7LDCX3CA items 1 apa default asc 1
Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4: Cell Reports. (n.d.). Retrieved January 5, 2021, from https://www.cell.com/cell-reports/fulltext/S2211-1247(20)31506-0 Cite
Investigators tested inhibitors of cap-dependent mRNA translation for the ability to sensitise diffuse large B-cell lymphoma and mantle cell lymphoma cells to apoptosis by venetoclax.
[British Journal of Cancer]
6445218 AFTAIZDT items 1 apa default asc 1
Herzog, L., Walters, B., Buono, R., Lee, J. S., Mallya, S., Fung, A., Chiu, H., Nguyen, N., Li, B., Pinkerton, A. B., Jackson, M. R., Schneider, R. J., Ronai, Z. A., & Fruman, D. A. (2020). Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. British Journal of Cancer, 1–12. https://doi.org/10.1038/s41416-020-01205-9 Cite
Functional characterization of intratumoral Tregs was performed by a proliferation assay using FACS-sorted Tregs as suppressor cells and autologous CellTrace Violet-labelled T effector cells as responder cells.
6445218 N2XPPLM3 items 1 apa default asc 1
Spasevska, I., Josefsson, S., Blaker, Y. N., Steen, C. B., Sharma, A., Kushekhar, K., Meyer, S., Kolstad, A., Beiske, K., Holte, H., Østenstad, B., Kimby, E., Olweus, J., Tasken, K., Lorenz, S., Smeland, E. B., Alizadeh, A. A., Huse, K., & Myklebust, J. H. (2020). Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma. Blood, 136(Supplement 1), 27–28. https://doi.org/10.1182/blood-2020-142380 Cite
Using normal and malignant lymphocytes from humans, and the phosphodiesterase 4b knockout mouse, scientists found that cAMP induced PD-L1 transcription and protein expression.
6445218 I82L4EYT items 1 apa default asc 1
Investigators performed a multicenter retrospective cohort study of patients with T-cell lymphoblastic lymphoma treated using leukemia-type initial therapies to compare the outcomes after hematopoietic stem cell transplantation at different disease stages.
6445212 6S4X33B4 items 1 apa default asc 1
Morita-Fujita, M., Arai, Y., Yoshioka, S., Ishikawa, T., Kanda, J., Kondo, T., Akasaka, T., Ueda, Y., Imada, K., Moriguchi, T., Yago, K., Kitano, T., Yonezawa, A., Nohgawa, M., & Takaori-Kondo, A. (2020). Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies. Scientific Reports, 10(1), 21418. https://doi.org/10.1038/s41598-020-78334-x Cite
Fate Therapeutics, Inc. announced positive interim data from the Company’s dose escalation Phase I study of FT516 in combination with rituximab for patients with relapsed/refractory B-cell lymphoma.
[Fate Therapeutics, Inc.]
6445212 nan items 1 apa default asc 1
Functional studies with gene-overexpressed and gene-silenced DLBCL cell lines showed that expression of NANOG and HOXA9 promoted cell viability and inhibited apoptosis through suppression of G2 arrest in vitro and enhanced tumor formation and hepatosplenic infiltration in a tail-vein-injected mouse model.
6445212 LAJW3B4N items 1 apa default asc 1
One of the major insights produced by such research is that diffuse large B-cell lymphoma (DLBCL) almost always stems from genetic damage that occurs during the germinal center reaction, which is required for the production of high-affinity antibodies.
[Blood Cancer Journal]
To identify the global regulatory networks controlling antigen presentation, scientists employed genome-wide screening in human diffuse large B cell lymphomas.
6445218 84QKF4NR items 1 apa default asc 1
Dersh, D., Phelan, J. D., Gumina, M. E., Wang, B., Arbuckle, J. H., Holly, J., Kishton, R. J., Markowitz, T. E., Seedhom, M. O., Fridlyand, N., Wright, G. W., Huang, D. W., Ceribelli, M., Thomas, C. J., Lack, J. B., Restifo, N. P., Kristie, T. M., Staudt, L. M., & Yewdell, J. W. (2020). Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 0(0). https://doi.org/10.1016/j.immuni.2020.11.002 Cite